AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Upstream Bio, Inc.
Video analysis: UPB
All videosNo video analysis for this stock yet. Request one from our team.
News: UPB
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma – – Verekitug also delivered clinically meaningful improvements in lung function (FEV 1 ) and exhaled nitric oxide (FeNO) with every 12-week dosing – – The Company remains on track to initiate Phase 3 trials in severe asthma and CRSwNP in Q1 2027 , designed to deliver best-in-class efficacy in both indications by evaluating a 400 mg quarterly regimen of verekitug in broad patient populations – WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for severe inflammatory respiratory diseases, today presented results from the Phase 2 VALIANT clinical trial evaluating the safety and efficacy of verekitug in adults with severe asthma in a late-breaking oral presentation at the European Respiratory Society (ERS) Congress 2026 in Barcelona.
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
– Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indication – – The Company's Phase 3 strategy is designed to deliver best-in-class efficacy across both indications by evaluating a high-dose, quarterly regimen of verekitug in broad patient populations – – The Company remains on track to initiate both Phase 3 trials in Q1 2027 – WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for severe inflammatory respiratory diseases, today announced its pivotal Phase 3 development plans for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).
Fannie Mae Announces Sale of Non-Performing Loans
Fannie Mae Announces Sale of Non-Performing Loans PR Newswire WASHINGTON, Aug. 19, 2026
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
Upstream Bio, Inc. (UPB) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $0.74 per share a year ago.
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
Upstream Bio, Inc. (UPB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Fannie Mae Announces the Results of its Thirty-sixth Reperforming Loan Sale Transaction
Fannie Mae Announces the Results of its Thirty-sixth Reperforming Loan Sale Transaction PR Newswire WASHINGTON,
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –
